Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Ann Intern Med. 2008 Jun 17;148(12):939-55. Epub 2008 May 5. Review.

2.

Hydroxyurea for the treatment of sickle cell disease.

Segal JB, Strouse JJ, Beach MC, Haywood C, Witkop C, Park H, Wilson RF, Bass EB, Lanzkron S.

Evid Rep Technol Assess (Full Rep). 2008 Mar;(165):1-95. Review.

3.

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Pediatrics. 2008 Dec;122(6):1332-42. doi: 10.1542/peds.2008-0441. Review.

PMID:
19047254
4.

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.

5.

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Blood Cells Mol Dis. 2000 Oct;26(5):453-66.

PMID:
11112383
6.

Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.

Hoppe C, Vichinsky E, Quirolo K, van Warmerdam J, Allen K, Styles L.

J Pediatr Hematol Oncol. 2000 Jul-Aug;22(4):330-4.

PMID:
10959903
7.

Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.

Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A.

Hemoglobin. 2012;36(4):323-32. doi: 10.3109/03630269.2012.697948.

PMID:
22734586
8.

Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.

Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, Visintainer P.

J Pediatr. 1996 Oct;129(4):559-65.

PMID:
8859263
9.

Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.

de Montalembert M, Belloy M, Bernaudin F, Gouraud F, Capdeville R, Mardini R, Philippe N, Jais JP, Bardakdjian J, Ducrocq R, Maier-Redelsperger M, Elion J, Labie D, Girot R.

J Pediatr Hematol Oncol. 1997 Jul-Aug;19(4):313-8.

PMID:
9256830
10.

Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.

Charache S.

Semin Hematol. 1997 Jul;34(3 Suppl 3):15-21. Review.

PMID:
9317197
11.

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries.

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Arch Dis Child. 2013 Nov;98(11):908-14. doi: 10.1136/archdischild-2012-302387. Epub 2013 Aug 30. Review.

12.

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.

JAMA. 2003 Apr 2;289(13):1645-51. Erratum in: JAMA. 2003 Aug 13;290(6):756.

PMID:
12672732
13.

Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.

DeBaun MR.

Expert Rev Hematol. 2014 Dec;7(6):767-73. doi: 10.1586/17474086.2014.959922. Epub 2014 Sep 22. Review.

PMID:
25242414
14.

Hydroxycarbamide for sickle-cell anaemia in infancy.

Weatherall DJ.

Lancet. 2011 May 14;377(9778):1628-30. doi: 10.1016/S0140-6736(11)60511-4. No abstract available.

PMID:
21571132
15.

Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.

Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S.

PLoS One. 2013;8(2):e55709. doi: 10.1371/journal.pone.0055709. Epub 2013 Feb 7.

16.

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; BABY HUG investigators..

Lancet. 2011 May 14;377(9778):1663-72. doi: 10.1016/S0140-6736(11)60355-3.

17.

Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.

Ware RE, Eggleston B, Redding-Lallinger R, Wang WC, Smith-Whitley K, Daeschner C, Gee B, Styles LA, Helms RW, Kinney TR, Ohene-Frempong K.

Blood. 2002 Jan 1;99(1):10-4.

18.

Hydroxyurea, sickle cell disease and renal transplantation.

Allen A, Scoble J, Snowden S, Hambley H, Bellingham A.

Nephron. 1997;75(1):106-7. No abstract available.

PMID:
9031282
19.

Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea.

Charache S, Terrin ML, Moore RD, Dover GJ, McMahon RP, Barton FB, Waclawiw M, Eckert SV.

Control Clin Trials. 1995 Dec;16(6):432-46.

PMID:
8925656
20.

[Hydroxyurea and other agents stimulating synthesis of fetal hemoglobin].

de Montalembert M.

Pathol Biol (Paris). 1999 Jan;47(1):55-8. Review. French.

PMID:
10081780

Supplemental Content

Support Center